Study 17 of 26Liraglutide literatureJAMATop journal2026
Compounded GLP-1 Drugs Remain Prevalent After Drug Shortage.
Not reported in abstract.
Where it sits
this study against the rest of the liraglutide corpus6
Preclinical · this one
13
Observational
0
Open-label
2
Randomised
5
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Liraglutide corpus
BReal-world treatment-transition pathways and dosing patterns of insulin degludec/liraglutide in Chinese adults with type 2 diabetes.Metabolism open · 2026 · n=1499 · Mean HbA1c decreased by 1.66 percentage points; P < 0.001.HumanBEconomic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran.Journal of diabetes and metabolic disorders · 2026 · Incremental cost-effectiveness ratio of US$34,423.89/QALY for tirzepatide compared with semaglutide.reviewDInflammatory mechanisms of pancreatic β-cell dysfunction and therapeutic strategies in type 2 diabetes mellitus: a narrative review.Journal of diabetes and metabolic disorders · 2026 · Not reported in abstract.reviewCEngineering 3'-UTR hairpin structures to modulate mRNA stability and recombinant protein production in Escherichia coli.Protein expression and purification · 2026 · n=6 · specific cellular fusion-protein content increased approximately 3-fold (p < 0.001, n=6)In vitroBEmerging Therapeutic Strategies for Infantile Obesity: A Narrative Reviewbiorxiv-preprint · 2026 · n=4331 · 1.71 kg/m² BMI reduction with medication plus behavioral treatment vs behavioral treatment alone, n=4331.reviewBPrevention of new-onset chronic kidney disease with renin-angiotensin system blockers in type 2 diabetes with preserved kidney function.Renal failure · 2026 · n=4725 · HR 0.72; 95% CI 0.60-0.86 for new-onset CKD with ACEI/ARB therapy.Human